

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Single Technology Appraisal

### AZD 3152 for preventing COVID-19 ID6282

#### Provisional Stakeholder list

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> <li>• AstraZeneca (AZD 3152)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Action for Pulmonary Fibrosis</li> <li>• Anthony Nolan</li> <li>• Blood Cancer UK</li> <li>• Cardiomyopathy UK</li> <li>• Cardiothoracic Transplant Patient Group</li> <li>• Chronic Lymphocytic Leukaemia Support Association</li> <li>• Clinically Vulnerable Families</li> <li>• Covid:Aid</li> <li>• Crohn's &amp; Colitis UK</li> <li>• Diabetes UK</li> <li>• Down's Syndrome Association</li> <li>• Forgotten lives UK</li> <li>• Immunodeficiency UK</li> <li>• Kidney Care UK</li> <li>• Kidney Research UK</li> <li>• Leukaemia Care</li> <li>• Long Covid Kids</li> <li>• Long COVID SOS</li> <li>• Long Covid Support</li> <li>• Lupus UK</li> <li>• Lymphoma Action</li> <li>• Metabolic Support UK</li> <li>• MS Society</li> <li>• Multiple Sclerosis Trust</li> <li>• Myeloma UK</li> <li>• National Kidney Federation</li> <li>• National Rheumatoid Arthritis Society</li> <li>• Polycystic Kidney Disease Charity</li> <li>• Sarcoidosis UK</li> <li>• Scleroderma and Raynaud's UK</li> <li>• Thrombosis UK</li> <li>• Vasculitis UK</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• All Wales Therapeutics and Toxicology Centre</li> <li>• British National Formulary</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Healthcare Improvement Scotland</li> <li>• Medicines and Healthcare products Regulatory Agency</li> <li>• Scottish Medicines Consortium</li> <li>• Welsh Government</li> <li>• Welsh Health Specialised Services Committee</li> </ul> <p><u>Comparator companies</u></p> <ul style="list-style-type: none"> <li>• None</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• Long Covid Research Initiative</li> <li>• Institute of Cancer Research</li> </ul> <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> <li>• UK Health Security Agency</li> </ul>

Stakeholder list for the single Technology Appraisal of AZD 3152 for preventing COVID-19 ID6282  
Issue date: May 2023.

Consultees	Commentators (no right to submit or appeal)
<p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• Association of British Neurologists</li> <li>• Association of Cancer Physicians</li> <li>• British HIV Association</li> <li>• British Infection Association</li> <li>• British Paediatric Allergy Infection and Immunity Group</li> <li>• British Society for Allergy and Clinical Immunology</li> <li>• British Society for Heart Failure</li> <li>• British Society for Immunology</li> <li>• British Thoracic Society</li> <li>• British Transplant Society</li> <li>• Cancer Research UK</li> <li>• Faculty of Pharmaceutical Medicine</li> <li>• Royal College of Physicians</li> <li>• UK Clinical Pharmacy Association</li> <li>• UK CLL Forum</li> <li>• UK Kidney Association</li> <li>• UK Renal Pharmacy Group</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health and Social Care</li> <li>• NHS England</li> </ul>	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

### Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts, and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

### Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

---

<sup>1</sup> Non-company consultees are invited to submit statements relevant to the group they are representing.